At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 45 enrolled
Drug / intervention
Mirikizumab- IV +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, Placebo-Controlled Study of LY3074828, an Anti-IL-23 Humanized Antibody
In Brief
A Phase 1 clinical trial evaluating Mirikizumab- IV, Mirikizumab - SC, and 1 other intervention for Psoriasis. Completed, enrolled 45 participants across 2 sites.
Detailed Summary
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug and how the drug affects the body. The study will last about 3 months for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartOct 2013
Primary CompletionFeb 2015
TodayJul 2026
First PostedSep 23, 2013
Enrollment StartOct 1, 2013
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.8 years ago
Interventions
Mirikizumab- IVbiological
Administered IV
Mirikizumab - SCbiological
Administered SC
Placebo - IVbiological
Administered IV